The COVID-19 virus has posed unparalleled challenges for both our healthcare systems and communities.
In 2020, the virus led to elevated mortality rates in critical care settings. As scientific understanding of this novel virus evolves, initial clinical reports and anatomical findings indicate that progressive hypoxemia is the primary driver of deterioration in COVID-19 patients.
As hypoxemia worsens, “standard therapy cannot effectively penetrate the diffusion barriers in the lungs due to limitations imposed by ambient pressure.” (2)
Preliminary evidence suggests that HBOT is not constrained by these barriers and may enhance the conditions of these patients, particularly when intervention is initiated at early stages.
Clinical research validates the following benefits of hyperbaric oxygen therapy for individuals with COVID-19. For links to the clinical studies, please see the bottom of this post.
If we extend these observations to the COVID-19 context, early intervention before the requirement for mechanical ventilation could be incredibly beneficial in saving lives. In this context, hyperbaric oxygen therapy (HBOT), involving exposure to 100% oxygen under increased atmospheric pressure up to 2.4 atm, could serve as a valuable resource to enhance outcomes from the infection when administered in the early stages, as soon as a reduction in arterial oxygen concentration is detected.
The information provided on this website is for educational purposes only and should not be viewed as a substitute for the diagnosis, treatment, or advice of a qualified licensed professional. This website offers general information and does not represent the practice of medicine. We do not take responsibility for how this information is utilized. Additionally, please note that the contents of this website are regularly updated for various reasons. Any statements or implied treatments have not been evaluated or approved by the FDA. It is crucial not to alter, discontinue, or change any medication or treatment without consulting your doctor first. Always seek your doctor’s advice before initiating any new treatment program.
The subsequent research article underscores the advantages of hyperbaric oxygen therapy for individuals who have experienced a traumatic brain injury.
If you have inquiries regarding a particular symptom or condition, please don't hesitate to reach out to us for assistance!
“Clinical reports and pathologic anatomic findings shown, progressive hypoxemia is the main cause of deterioration in patients with COVID-19. ‘The mortality rate of critical patients in WuHan is close to 60%, and we are trying to solve the problem of hypoxia,’ Zhong Nanshan said on 27 th Feb. HBOT is the strongest non-invasive oxygen therapy. In the early stage, 5 cases of severe and critical patients with COVID-19 a were clinically treated, which proved that the long-term excellent clinical effect of using HBOT in treating hypoxia was also applicable to COVID-19 patients.”
Learn about purchase and rental programs.
Copyright © 2024 Hyperbaric Hub LLC All Rights Reserved
